iBio Q1 fiscal 2025: net loss $4.0M ($0.46/sh), no revenue; advancing myostatin NHP study

iBio, Inc.

2025-Q1 EPS reported -$0.46

No revenue for quarter ended Sep 30, 2024; net loss from continuing ops $4.0M ($0.46/sh) vs $5.1M ($4.24/sh) YoY.
R&D and G&A expenses decreased ~20% YoY to $4.1M as part of cash preservation strategy.
Cash, equivalents, and restricted cash $11.3M at Sep 30, 2024 (incl $0.2M restricted).
Collaboration with AstralBio: lead molecule for muscle wasting/obesity dosed in NHP study; early readouts expected early 2025.
Appointed Kristi Sarno as SVP of Business Development effective Aug 1, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.